A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

Trial Profile

A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Fallopian tube cancer; Gastric cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Umbrella
  • Sponsors Ipsen
  • Most Recent Events

    • 10 Aug 2017 Status changed from active, no longer recruiting to completed, based on the results published in the Targeted Oncology.
    • 10 Aug 2017 Results published in the Targeted Oncology
    • 13 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top